Clinic
Methodist Children's Hospital
Methodist Children's Hospital was paid $12.69M by Medicaid between Jan 2018 and Dec 2024, across 145 billing codes. Its largest line is 99284, emergency room visit (serious) — 23% of everything it billed.
33Billing provider infoMETHODIST CHILDREN'S HOSPITAL
LUBBOCK, TX 79410
LUBBOCK, TX 79410
33aNPI1437171568assigned 07/25/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$12.69M
24GClaims163,925
24DCodes billed145
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#38 of 320
Median peer was paid$205K
This provider vs. median62×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,021 | $20K | |
| 2019 | 961 | $15K | |
| 2020 | 2,905 | $200K | |
| 2021 | 29,347 | $2.53M | |
| 2022 | 46,982 | $3.82M | |
| 2023 | 48,394 | $3.85M | |
| 2024incomplete | 34,315 | $2.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 23% | 8,416 | 8,161 | $2.93M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 25,312 | 24,780 | $2.17M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 11% | 3,337 | 1,398 | $1.36M |
| G0378 | Hospital observation service, per hour | 8.0% | 1,858 | 1,139 | $1.01M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.7% | 1,854 | 1,819 | $979K |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.3% | 378 | 274 | $548K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 3,532 | 3,443 | $278K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.0% | 3,205 | 3,174 | $254K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 19,545 | 16,670 | $228K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.6% | 72 | 71 | $209K |
| 80053 | Comprehensive metabolic panel | 1.6% | 12,769 | 10,951 | $204K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.6% | 842 | 512 | $199K |
133 more codes
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.2% | 3,089 | $154K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 1,342 | $153K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.1% | 4,795 | $135K |
| 76770 | 1.0% | 539 | $133K | |
| 86780 | <1% | 3,193 | $85K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,888 | $80K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,915 | $79K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,770 | $78K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 471 | $74K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,201 | $70K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 605 | $69K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 577 | $62K |
| 84702 | <1% | 2,114 | $58K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 947 | $58K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 493 | $52K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 773 | $41K |
| 86762 | <1% | 1,281 | $37K | |
| 36591 | <1% | 867 | $36K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 367 | $36K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 841 | $36K |
| 86850 | <1% | 1,941 | $35K | |
| 87340 | <1% | 1,651 | $34K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 27 | $34K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 792 | $33K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 444 | $28K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 445 | $28K |
| 86803 | <1% | 801 | $26K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 531 | $26K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 463 | $25K |
| 0353U | <1% | 711 | $25K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,586 | $24K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,572 | $24K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 191 | $24K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 40 | $19K |
| 74018 | <1% | 385 | $19K | |
| 80061 | Lipid panel | <1% | 648 | $17K |
| 86900 | <1% | 1,877 | $17K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,149 | $15K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 400 | $15K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 297 | $15K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,891 | $15K |
| 82950 | <1% | 1,181 | $14K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 12 | $14K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 493 | $14K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 43 | $13K |
| 86705 | <1% | 450 | $13K | |
| 84439 | <1% | 888 | $13K | |
| 83655 | <1% | 447 | $13K | |
| 86787 | <1% | 413 | $12K | |
| 86901 | <1% | 1,858 | $11K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 460 | $9K |
| 96367 | <1% | 154 | $9K | |
| 84144 | <1% | 191 | $9K | |
| 81001 | <1% | 1,648 | $8K | |
| 86140 | <1% | 925 | $7K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 32 | $7K |
| 88313 | <1% | 65 | $6K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 518 | $6K |
| 85027 | <1% | 350 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 218 | $5K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 46 | $5K |
| 83615 | <1% | 799 | $5K | |
| 99220 | <1% | 24 | $5K | |
| 80050 | General health panel | <1% | 46 | $5K |
| 81002 | <1% | 742 | $4K | |
| 82728 | <1% | 326 | $4K | |
| 86300 | <1% | 166 | $4K | |
| 81000 | <1% | 598 | $3K | |
| 88342 | <1% | 61 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 38 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 701 | $3K |
| 88312 | <1% | 49 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 56 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $3K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 170 | $3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 169 | $3K |
| 96417 | <1% | 21 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 30 | $2K |
| J3490 | Unclassified drugs | <1% | 55 | $2K |
| 87070 | <1% | 353 | $2K | |
| 74019 | <1% | 39 | $2K | |
| 81025 | <1% | 270 | $2K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 15 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 18 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 334 | $2K |
| 81003 | <1% | 482 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $2K |
| 83550 | <1% | 186 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 24 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 156 | $1K |
| 86706 | <1% | 53 | $1K | |
| 83540 | <1% | 202 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 119 | $1K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 56 | $990.63 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 130 | $989.20 |
| 87040 | <1% | 89 | $944.66 | |
| 82570 | <1% | 96 | $923.19 | |
| 87634 | <1% | 13 | $881.62 | |
| 96376 | <1% | 17 | $815.60 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 36 | $809.88 |
| 82784 | <1% | 71 | $804.51 | |
| 87807 | <1% | 84 | $767.85 | |
| 86364 | <1% | 24 | $725.35 | |
| 85018 | <1% | 122 | $715.93 | |
| 85014 | <1% | 122 | $715.93 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 117 | $663.67 |
| 76642 | <1% | 12 | $653.59 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 59 | $638.08 |
| 85652 | <1% | 136 | $617.63 | |
| J0735 | Injection, clonidine hydrochloride, 1 mg | <1% | 12 | $570.58 |
| 84156 | <1% | 84 | $552.00 | |
| 82378 | <1% | 74 | $492.51 | |
| 90837 | Psychotherapy session, about an hour | <1% | 20 | $359.70 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 75 | $357.68 |
| 85046 | <1% | 30 | $348.63 | |
| 83735 | <1% | 29 | $302.50 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 134 | $285.54 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 16 | $223.80 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 19 | $159.30 |
| 82657 | <1% | 14 | $153.70 | |
| 83690 | <1% | 15 | $150.99 | |
| 84550 | <1% | 13 | $143.57 | |
| 82951 | <1% | 13 | $143.18 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 46 | $127.35 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $123.11 |
| 85045 | <1% | 17 | $80.14 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 15 | $73.95 |
| 80143 | <1% | 13 | $43.69 | |
| 80179 | <1% | 13 | $43.69 | |
| 82952 | <1% | 12 | $43.62 | |
| 87077 | <1% | 12 | $43.17 | |
| 82077 | <1% | 13 | $40.48 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 289 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY OF ENROLLMENTS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.